Proteomika. Biomarcadores para el diagnóstico no invasivo de enfermedades complejas.

04
  1. Inicio
  2. Publicaciones


Separador

Img promonitor

Publicaciones (peer reviewed)

Todos los kits Promonitor cuentan con un sólido respaldo en las principales publicaciones


  1. Cordero-Coma M, Calleja-Antolín S, Garzo-García I et al.Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring serum Drug Levels and Antidrug Antibodies. Ophthalmology 2016;123(12):2618-25.27692527
  2. Freeman K, Connock M, Auguste P et al. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20(83):1-288.27845027
  3. Ghia C, Akerkar S, Sabnis S et al. Analytical and clinical evaluation of an immunoassay for estimating immunogenicity of infliximab and etanercept in Indian population. J Assoc Physicians India 2016;64:14-17
  4. Gupta R and Misra R Measuring Anti-drug Antibodies: A Step Towards Optimization of Biologic Therapy. J Assoc Physicians India 2016;64:Editorial
  5. Marini JC, Sendecki J, Cornillie F et al. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade. AAPS J 2016 Sep 6 [Epub ahead of print] 27600137
  6. Elberdín L, Outeda M, Salvador P et al. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value. Int J Clin Pharm 2016 Jul 19 [Epub ahead of print] 27436193
  7. Laine J, Jokiranta TS, Eklund KK et al. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers. Biologics 2016 Apr 1;10:67-73. 27099470
  8. Jani M, Isaacs JD, Morgan AW et al. Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology (Oxford) 2016 Aug 25. pii: kew299 [Epub ahead of print]. 27565176
  9. Jani M, Gavan S, Chinoy H et al. A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology (Oxford) 2016 Aug 29. pii: kew292 [Epub ahead of print]. 27576368
  10. Inciarte-Mundo J, Ramírez J, Hernández MV et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther 2016;18(1):160. 27391315
  11. Almirall M, Gimeno R, Salman-Monte TC et al. Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy. Rheumatol Int [Epub ahead of print] 2016. 26815206
  12. Guiotto C, Daperno M, Frigerio F et al. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Dig Liver Dis 2016;48(2):138-43. 26614644
  13. Ruiz-Arguello MB, Maguregui A, Ruiz Del AA et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis 2016. 26965981
  14. Arstikyte I, Kapleryte G, Butrimiene I et al. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF alpha Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. Biomed Res Int 2015;2015:604872. 26064930
  15. Bandres CS, Salvatierra J, Lopez-Sidro M et al. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. J Clin Rheumatol 2015;21(3):115-9. 25807089
  16. Chen DY, Chen YM, Hsieh TY et al. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford) 2015. 26324949
  17. Chen DY, Chen YM, Hung WT et al. Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment. Ann Rheum Dis 2015;74(12):2261-4. 26443609
  18. Elberdin L, Outeda M, Salvador P et al. Infliximab drug and antibody levels in patients with dermatological conditions. Int J Clin Pharm 2015;37(2):320-6. 25612566
  19. Fabris M, Pistis C, Zabotti A et al. The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared. Drug Metab Lett 2015;9(2):132-7. 26256298
  20. Jani M, Chinoy H, Warren RB et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet 2015;385 Suppl 1:S48. 26312870
  21. Llinares-Tello F, Rosas-Gomez de SJ, Senabre-Gallego JM et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of etanercept. Clin Chem Lab Med 2015;53(10):e279-e282. 26021413
  22. Martin S, del Agua AR, Torres N et al. Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases. Clin Chem Lab Med 2015;53(11):e297-e299. 25945722
  23. Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P et al. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Ann Rheum Dis 2015;74:e42. 25805737
  24. Schmitz EM, van de Kerkhof D, Hamann D et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med 2015. 26587745
  25. Valor L, Hernandez-Florez D, de lT, I et al. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison. Clin Exp Rheumatol 2015;33(5):617-23. 26316061
  26. Valor L, Hernandez-Florez D, de lT, I et al. Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients. Clin Exp Rheumatol 2015;33(6):805-11. 26314759
  27. Zisapel M, Zisman D, Madar-Balakirski N et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol 2015;42 (1):73-8. 25399390
  28. Chen DY, Chen YM, Tsai WC et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2014;74(3):e16. 24442879 
  29. Hernandez-Florez D, Valor L, de lT, I et al. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis. Rheumatol Int 2014. 25410014
  30. Llinares-Tello F, Rosas-Gomez de SJ, Senabre-Gallego JM et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014;34(12):1701-8. 24816715
  31. Llinares-Tello F, Rosas J, de lT, I et al. Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis. Reumatol Clin 2014;10(2):105-8. 24035361
  32. Marinari B, Botti E, Bavetta M et al. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations. Drug Dev Res 2014;75 Suppl 1:S11-S14. 25381966
  33. Mazilu D, Opris D, Gainaru C et al. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Int 2014;2014:702701. 24982902
  34. Rosas J, Llinares-Tello F, de lT, I et al. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. Clin Exp Rheumatol 2014;32(6):942-8. 25327159
  35. Zamora-Atenza C, Diaz-Torne C, Geli C et al. Adalimumab regulates intracellular TNFalpha production in patients with rheumatoid arthritis. Arthritis Res Ther 2014;16(4):R153. 25037855
  36. Ruiz-Arguello B, del Agua AR, Torres N et al. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51 (12):e287-e289. 23917475
  37. Llinares F, Rosas-Gómez de Salazar J, Senabre-Gallego JM et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012;50:1845-7. 23089717
  38. Plasencia C, Pascual-Salcedo D, Nuño L et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955-60. 22563028
  39. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50(8):1445-52. 21427177

Promonitor cuenta con mas de 100 abstracts publicados en los principales congresos internacionales